Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10009972HBVENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS10009973HBVENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS10025398HBVENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS10051379HBVENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS10047811HBVENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS30082660HIVENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS30074452HIVENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS30020631HIVENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS30054480HIVENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TVIS20044142HPVENSG00000142192.22protein_codingAPPNoNo351A0A0A0MRG2
E9PG40
P05067
TCGA Plot Options
Drug Information
GeneAPP
DrugBank IDDB14580
Drug NameLecanemab
Target IDBE0003392
UniProt IDP05067
Regulation Typebinder
PubMed IDs27048170; 33865446
CitationsLogovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L: Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016 Apr 6;8(1):14. doi: 10.1186/s13195-016-0181-2.@@Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.
GroupsApproved; Investigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBL